％0期刊文章％a Stievenart，Julien％le Guenno，Guillaume％ruivard，Marc％rieu，virginie％André，Marc％A grobost，Vincent％T心脏曲折：皮质类固醇和免疫抑制性治疗的文献综述D 2021％r 10.1183/13993003.00449-2021％J欧洲呼吸期杂志％p 2100449％x背景心脏结节病（CS）是一种危及生命的条件，缺乏明确的建议。我们的目的是系统地审查有关皮质类固醇和/或免疫抑制剂治疗的心脏结节病的文献，以便使用PubMed，Embase和Cochrane库数据库更新CS.S.Methods的管理，我们发现了有关皮质类固醇和/或标准免疫抑制性治疗的原始文章。CS至少提供了公平标志的总体评估质量并分析复发率，重大心脏不良事件（MACE）和不良事件。我们将方法基于Prisma声明和清单。我们检索了21项研究。标志评估提供的平均质量为6.8/14（范围5-9）。皮质类固醇似乎对左心室功能，心房阻滞和心室心律不齐有积极影响。对于仅皮质类固醇，九项研究（45％）研究（n = 351）提供了有关复发的数据，代表34％的发病率（n = 119）。三项研究（14％，n = 73）提供了有关MACES的数据（n = 33），仅由皮质类固醇治疗的患者中的45％的MACE。九项研究提供了有关辅助免疫抑制疗法的数据，其中四项研究（n = 78）提供了有关CS复发的数据，代表发生率为33％（n = 26）。限制包括未检索的随机对照试验和对通过免疫抑制剂和皮质类固醇治疗的患者的MACE的不清楚数据。结论性皮质类固醇应在诊断后尽早开始，但确切的方案尚不清楚。 Studies concerning adjunctive conventional immunosuppressive therapies are lacking and benefits of adjunctive immunosuppressive therapies are unclear. Homogenous data on CS long-term outcomes under corticosteroids, immunosuppressive therapies and other adjunctive therapies are lacking.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. STIEVENART has nothing to disclose.Conflict of interest: Dr. Le Guenno has nothing to disclose.Conflict of interest: Dr. RUIVARD has nothing to disclose.Conflict of interest: Dr. RIEU has nothing to disclose.Conflict of interest: Dr. ANDRE has nothing to disclose.Conflict of interest: Dr. vincent has nothing to disclose. %U //www.qdcxjkg.com/content/erj/early/2021/08/26/13993003.00449-2021.full.pdf